Retatrutide cuts apnea-hypopnea index by up to 24 events hourly
Two parallel randomized trials, published in NEJM, tested the GIP/GLP-1/glucagon triple agonist in adults with obesity or overweight, with and without type 2 diabetes.
MH
By Maren Holt · Senior Reporter, GLP-1
Oct 21 11:59 ETSource: MedPage Today
The wire
- 01In TRIUMPH-1-OSA, 9 mg and 12 mg retatrutide lowered AHI at 80 weeks by 24.4 and 21.9 events per hour versus placebo; TRIUMPH-2-OSA, in type 2 diabetes, showed 14.4 and 15.1.
- 02Weight loss reached 12.5-22.2% and 12.1-18.5% across the trials versus 4.8% and 5.6% on placebo, giving sleep clinicians a possible second incretin option beyond tirzepatide.
- 03Commentators said results look similar to, not better than, tirzepatide's SURMOUNT-OSA data despite the triple-agonist mechanism; retatrutide is not approved for obstructive sleep apnea.
From the source
Read at medpagetoday.comAnother Incretin Drug Proves Mettle in Sleep Apnea
— Novel retatrutide worked in overweight, obese adults with and without type 2 diabetes
